Pfizer Inc. (NYSE: PFE) today announced the Phase 2b results of a 24 week, randomized, placebo-controlled, dose-ranging study of investigational bococizumab, the proposed generic name for RN316. Statin treated patients with high cholesterol were randomized to various doses of either bococizumab twice or once monthly subcutaneous administration or placebo. The study met its primary endpoint across all doses, showing that bococizumab significantly reduced low density lipoprotein cholesterol (LDL-C) from baseline compared to placebo in adults with high cholesterol also taking statin therapy. 1 The percentage of patients reporting adverse events or serious adverse events was similar across placebo- and bococizumab-treatment groups. The Phase 3 program for bococizumab was initiated in October 2013.
Elevated LDL-C is recognized as a major risk factor for cardiovascular disease, 2 the number one cause of death worldwide despite the widespread availability of statin therapy. 3
“I am hopeful that bococizumab, as a member of the PCSK9 class, will play an important role in understanding and addressing the unmet need for patients at high risk for cardiovascular events. The Phase 3 CV outcome studies for this class of medicine will be the most critical in defining future clinical practice,” said Christie M Ballantyne, Chief of the Section of Cardiology and Cardiolvascular Research from Baylor College of Medicine.
This dose-ranging, double-blind, placebo-controlled study in 354 patients examined two dosing regimens: twice monthly (bococizumab 50 mg, 100 mg or 150 mg) and once monthly (bococizumab 200 mg or 300 mg). For both regimens, the bococizumab dose was lowered if LDL-C was reduced to ≤25 mg/dL. The first opportunity for dose reduction was at Week 6 for the twice monthly and Week 8 for the once monthly regimen. The primary efficacy analysis was the placebo-adjusted change from baseline in LDL-C at Week 12. 1 The mean baseline LDL across doses was 109 mg/dL.Bococizumab twice and once monthly dosing regimens were associated with significant placebo-adjusted reductions in LDL-C at Week 12, with the greatest reductions seen with 150 mg for the twice monthly regimen and 300 mg for the once monthly regimen. 1 Prior to the majority of dose reductions due to an LDL-C ≤25mg/dL, the LDL-C changes seen with these regimens were greater than those observed at Week 12 (primary endpoint). 1
|Dosing regimens 1||
Mean change from
baseline in LDL-C at
Week 12 (placebo-adjusted)
Maximum mean change
from baseline in
|150mg twice monthly||-53.4 mg/dL||-66.9 mg/dL (week 8)|
|300mg once monthly||-44.9 mg/dL||-54.9 mg/dL (week 4)|